This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a). To learn more, click here. 

The RiNeuD study is a clinical research study for people who have type 1 or type 2 diabetes that has led to painful DPN. The goal of the RiNeuD study is to find out if the study medication can provide relief from the pain, tingling, and numbness associated with painful DPN. The study medication may be able to restore cells, called neurons, that transport messages between the brain and other parts of the body. 

Who can join the study? 

You may be able to join the RiNeuD study if you meet the following study requirements*: 

• Between 18 and 80 years of age
• Diagnosed with diabetes (type 1 or type 2) at least 6 months ago
• Have pain, tingling, numbness, or weakness in the hands, legs or feet

Endometriosis is a painful disorder of the uterus affecting 6-10% of women of childbearing age. Endometriosis affects daily activities, social relationships, sexuality and sexual activity, and mental health. This study will evaluate how well elagolix in combination with combined oral contraceptives (COC) works within the body and/or how safe it is compared to placebo (does not contain treatment drug). This study will assess the dysmenorrhea (painful periods) response in participants with endometriosis and associated pain. To learn more about this study, call us at 843-851-7098 or click here. 

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab (Repatha) on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event. To learn more, click here. 

Triglycerides are a type of fat that can be measured in the blood. They are the most common type of fat in the human body. They can come directly from foods, especially butter, oils, and other fatty foods, including red meat. Having persistently high levels of triglycerides (sometimes called severe hypertriglyceridemia) can raise the risk of heart disease and stroke.

This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (QW or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 compared to placebo in subjects with Severe Hypertriglyceridemia (SHTG). To learn more about this study, click here. 

Consider joining the TRAVERSE research study for men age 45-80 who have symptoms of low testosterone (hypogonadism) and have a history or risk of heart disease or stroke.

If you volunteer and qualify, your participation will last up to approximately 5 years. To learn more visit our contact us page or click here.

Randomized, double-blind, parallel-group, multicenter study to assess efficacy, safety, and tolerability of oral tropifexor & licogliflozin combination therapy, compared to each monotherapy, for treatment of adult patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. To learn more, click here. 

The GOAL study will check whether a patch that contains a pain medication  (a study drug patch) works and if it is safe for people with knee pain caused by osteoarthritis (OA). The study drug patch will be compared with another patch called a placebo patch. A placebo patch looks like the same as the study drug patch but contains no pain medication. 

You are someone you care for may be able to take part if you/they: 

• are 40-85 years of age
• Have been diagnosed with OA of the knee
• are experiencing knee pain caused by OA.

About 352 people will join the GOAL study at study centers across the USA. To learn more, click here. 

This clinical research study is assessing different doses of a study drug. The goal is to find out how people with type 2 diabetes tolerate increasing doses of the study drug. 

This clinical research study may be an option for you if: 

• you are aged between 18 and 75 years old.
• you are being treated for type 2 diabetes with at least 500mg/day of metformin
• you have no other serious medical or psychiatric conditions

If you join this clinical research study, you will take part for up to 22 weeks. You can expect to visit the study site about 10 times with one follow-up telephone call. To learn more, click here.